55667-17-9 Usage
Uses
Used in Pharmaceutical Industry:
3-(Benzyloxy)-4-methoxybenzaldehyde oxime is used as a building block for the preparation of various pharmaceuticals. Its antioxidant and anti-inflammatory properties contribute to the development of new drugs for treating a range of diseases, including inflammatory and oxidative stress-related conditions.
Used in Agrochemical Industry:
3-(Benzyloxy)-4-methoxybenzaldehyde oxime is utilized as a key intermediate in the synthesis of agrochemicals, such as pesticides and herbicides. Its unique chemical structure allows for the creation of effective compounds that can protect crops from pests and diseases.
Used in Organic Synthesis:
3-(Benzyloxy)-4-methoxybenzaldehyde oxime serves as a valuable reagent in organic synthesis, enabling the preparation of a variety of organic compounds with diverse applications. Its versatility in chemical reactions makes it an essential component in the development of new chemical entities.
Used in Chemical Research and Development:
As a chemical compound with unique properties, 3-(Benzyloxy)-4-methoxybenzaldehyde oxime is widely used in chemical research and development. It aids in understanding the structure-activity relationships of various compounds and contributes to the discovery of novel chemical entities with potential applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 55667-17-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,5,6,6 and 7 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 55667-17:
(7*5)+(6*5)+(5*6)+(4*6)+(3*7)+(2*1)+(1*7)=149
149 % 10 = 9
So 55667-17-9 is a valid CAS Registry Number.
InChI:InChI=1/C15H15NO3/c1-18-14-8-7-13(10-16-17)9-15(14)19-11-12-5-3-2-4-6-12/h2-10,17H,11H2,1H3/b16-10-
55667-17-9Relevant academic research and scientific papers
PHOSPHODIESTERASE INHIBITORS
-
Page/Page column 9, (2010/03/02)
The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Compounds disclosed herein can be useful in the treatment of CNS diseases, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and their use as PDE type IV selective inhibitors, are provided.
An efficient method for the preparation of nitriles via the dehydration of aldoximes with phthalic anhydride
Wang, Eng-Chi,Huang, Keng-Shiang,Chen, Hsing-Ming,Wu, Chung-Chin,Lin, Gwo-Jiun
, p. 619 - 627 (2007/10/03)
A new and highly efficient method for the conversion of aldoximes to nitriles was established. By fusing with phthalic anhydride, aldoximes were efficiently and smoothly converted into nitriles, in high yields (over 85%) and in a short time (within 5 minutes). The mixture of phthalic anhydride, a cyclic anhydride, and aldoximes in fusing state set up an ideal transition state for a selective [3.3]-sigmatropic rearrangement of the acylated aldoximes to nitriles.
A Facile Total Synthesis of (+/-)-Cherylline via an Aziridinium Intermediate
Kametani, Tetsuji,Higashiyama, Kimio,Honda, Toshio,Otomasu, Hirotaka
, p. 2935 - 2938 (2007/10/02)
The 4-aryl-1,2,3,4-tetrahydroisoquinoline alkaloid, (+/-)-cherylline (1), has been synthesised by a ring-opening reaction of the quaternary aziridinium salt, followed by a cyclisation of the quinone methide.
